Interleukin-17 regulates the expressions of RANKL and OPG in human periodontal ligament cells via TRAF6/TBK1-JNK/NF-kB pathways

Immunology

Volumn 144, Issue 3, 2015, Pages 472-485

  Lin, Danping ^a   Li, Lu ^a,b   Sun, Ying ^a,b   Wang, Weidong ^a   Wang, Xiaoqian ^a   Ye, Yu ^a   Chen, Xu ^a   Xu, Yan ^a,b  

^a NANJING MEDICAL UNIVERSITY   (China)

^b Jiangsu Province Engineering Research Center of Stomatological Translational Medicine   (China)

Author keywords

interleukin 17; osteoprotegerin; periodontal ligament cells; receptor activator for nuclear factor kB ligand; signal transduction

Indexed keywords

EID: 85026311350     PISSN: 00192805     EISSN: 13652567     Source Type: Journal    
DOI: 10.1111/IMM.12395     Document Type: Article

References (44)

1. Gor DO, Rose NR, Greenspan NS. TH1-TH2: a procrustean paradigm. Nat Immunol 2003; 4:503–5.
2. Korn T, Bettelli E, Oukka M, Kuchroo VK. IL-17 and Th17 Cells. Annu Rev Immunol 2009; 27:485–517.
3. Tesmer LA, Lundy SK, Sarkar S, Fox DA. Th17 cells in human disease. Immunol Rev 2008; 223:87–113.
4. Bettelli E, Korn T, Kuchroo VK. Th17: the third member of the effector T cell trilogy. Curr Opin Immunol 2007; 19:652–7.
5. Bi Y, Liu G, Yang R. Th17 cell induction and immune regulatory effects. J Cell Physiol 2007; 211:273–8.
6. Raychaudhuri SP. Role of IL-17 in psoriasis and psoriatic arthritis. Clin Rev Allergy Immunol 2013; 44:183–93.
7. Cardoso CR, Garlet GP, Crippa GE, Rosa AL, Junior WM, Rossi MA, Silva JS. Evidence of the presence of T helper type 17 cells in chronic lesions of human periodontal dis-ease. Oral Microbiol Immunol 2009; 24:1–6.
8. Shaker OG, Ghallab NA. IL-17 and IL-11 GCF levels in aggressive and chronic peri-odontitis patients: relation to PCR bacterial detection. Mediators Inflamm 2012; 2012:174764.
9. Adibrad M, Deyhimi P, Ganjalikhani Hakemi M, Behfarnia P, Shahabuei M, Rafiee L. Signs of the presence of Th17 cells in chronic periodontal disease. J Periodontal Res 2012; 47:525–31.
10. Zhao L, Zhou Y, Xu Y, Sun Y, Li L, Chen W. Effect of non-surgical periodontal therapy on the levels of Th17/Th1/Th2 cytokines and their transcription factors in Chinese chronic periodontitis patients. J Clin Periodontol 2011; 38:509–16.
11. Moon YM, Yoon BY, Her YM et al. IL-32 and IL-17 interact and have the potential to aggravate osteoclastogenesis in rheumatoid arthritis. Arthritis Res Ther 2012; 14:R246.
12. Zhang F, Wang CL, Koyama Y et al. Compressive force stimulates the gene expression of IL-17s and their receptors in MC3T3-E1 cells. Connect Tissue Res 2010; 51:359–69.
13. Hayashi N, Yamaguchi M, Nakajima R, Utsunomiya T, Yamamoto H, Kasai K. T-helper 17 cells mediate the osteo/odontoclastogenesis induced by excessive orthodontic forces. Oral Dis 2012; 18:375–88.
14. Huang H, Kim HJ, Chang EJ, Lee ZH, Hwang SJ, Kim HM, Lee Y, Kim HH. IL-17 stimulates the proliferation and differentiation of human mesenchymal stem cells: implications for bone remodeling. Cell Death Differ 2009; 16:1332–43.
15. Eskan MA, Jotwani R, Abe T et al. The leukocyte integrin antagonist Del-1 inhibits IL-17-mediated inflammatory bone loss. Nat Immunol 2012; 13:465–73.
16. Yasuda H, Shima N, Nakagawa N et al. Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/ RANKL. Proc Natl Acad Sci USA 1998; 95:3597–602.
17. Nakashima T, Kobayashi Y, Yamasaki S, Kawakami A, Eguchi K, Sasaki H, Sakai H. Protein expression and functional difference of membrane-bound and soluble receptor activator of NF-kappaB ligand: modulation of the expression by osteotropic factors and cytokines. Biochem Biophys Res Commun 2000; 275:768–75.
18. Han X, Lin X, Yu X, Lin J, Kawai T, LaRosa KB, Taubman MA. Porphyromonas gingi-valis infection-associated periodontal bone resorption is dependent on receptor activator of NF-kappaB ligand. Infect Immun 2013; 81:1502–9.
19. Belibasakis GN, Bostanci N. The RANKL-OPG system in clinical periodontology. J Clin Periodontol 2012; 39:239–48.
20. Hasegawa T, Yoshimura Y, Kikuiri T, Yawaka Y, Takeyama S, Matsumoto A, Oguchi H, Shirakawa T. Expression of receptor activator of NF-kappa B ligand and osteopro-tegerin in culture of human periodontal ligament cells. J Periodontal Res 2002; 37:405– 11.
21. Nishijima Y, Yamaguchi M, Kojima T, Aihara N, Nakajima R, Kasai K. Levels of RANKL and OPG in gingival crevicular fluid during orthodontic tooth movement and effect of compression force on releases from periodontal ligament cells in vitro. Orthod Craniofac Res 2006; 9:63–70.
22. Kanzaki H, Chiba M, Shimizu Y, Mitani H. Periodontal ligament cells under mechanical stress induce osteoclastogenesis by receptor activator of nuclear factor kappaB ligand up-regulation via prostaglandin E2 synthesis. J Bone Miner Res 2002; 17:210–20.
23. Song X, Qian Y. IL-17 family cytokines mediated signaling in the pathogenesis of inflammatory diseases. Cell Signal 2013; 25:2335–47.
24. Ouyang H, McCauley LK, Berry JE, D’Errico JA, Strayhorn CL, Somerman MJ. Response of immortalized murine cementoblasts/periodontal ligament cells to parathyroid hormone and parathyroid hormone-related protein in vitro. Arch Oral Biol 2000; 45:293–303.
25. Schwandner R, Yamaguchi K, Cao Z. Requirement of tumor necrosis factor receptor-associated factor (TRAF)6 in interleukin 17 signal transduction. J Exp Med 2000; 191:1233–40.
26. Qu F, Gao H, Zhu S et al. TRAF6-dependent Act1 phosphorylation by the IkappaB kinase-related kinases suppresses interleukin-17-induced NF-kappaB activation. Mol Cell Biol 2012; 32:3925–37.
27. Wada N, Maeda H, Tanabe K, Tsuda E, Yano K, Nakamuta H, Akamine A. Periodontal ligament cells secrete the factor that inhibits osteoclastic differentiation and function: the factor is osteoprotegerin/osteoclastogenesis inhibitory factor. J Periodontal Res 2001; 36:56–63.
28. Bloemen V, Schoenmaker T, de Vries TJ, Everts V. Direct cell-cell contact between periodontal ligament fibroblasts and osteoclast precursors synergistically increases the expression of genes related to osteoclastogenesis. J Cell Physiol 2010; 222:565–73.
29. Zhu L, Wu Y, Wei H, Xing X, Zhan N, Xiong H, Peng B. IL-17R activation of human periodontal ligament fibroblasts induces IL-23 p19 production: Differential involvement of NF-kappaB versus JNK/AP-1 pathways. Mol Immunol 2011; 48:647–56.
30. Wu Y, Zhu L, Liu L, Zhang J, Peng B. Interleukin-17A stimulates migration of periodontal ligament fibroblasts via p38 MAPK/NF-kappaB-dependent MMP-1 expression. J Cell Physiol 2014; 229:292–9.
31. Vernal R, Dutzan N, Chaparro A, Puente J, Antonieta Valenzuela M, Gamonal J. Levels of interleukin-17 in gingival crevicular fluid and in supernatants of cellular cultures of gingival tissue from patients with chronic periodontitis. J Clin Periodontol 2005; 32:383–9.
32. Song X, Qian Y. The activation and regulation of IL-17 receptor mediated signaling. Cytokine 2013; 62:175–82.
33. van den Berg WB, McInnes IB. Th17 cells and IL-17 a–focus on immunopathogenesis and immunotherapeutics. Semin Arthritis Rheum 2013; 43:158–70.
34. Sun D, Novotny M, Bulek K, Liu C, Li X, Hamilton T. Treatment with IL-17 prolongs the half-life of chemokine CXCL1 mRNA via the adaptor TRAF5 and the splicing-regu-latory factor SF2 (ASF). Nat Immunol 2011; 12:853–60.
35. Wang Y, Zhang P, Liu Y, Cheng G. TRAF-mediated regulation of immune and inflammatory responses. Sci China Life Sci 2010; 53:159–68.
36. Lomaga MA, Yeh WC, Sarosi I et al. TRAF6 deficiency results in osteopetrosis and defective interleukin-1, CD40, and LPS signaling. Genes Dev 1999; 13:1015–24.
37. Mao R, Fan Y, Mou Y, Zhang H, Fu S, Yang J. TAK1 lysine 158 is required for TGF-beta-induced TRAF6-mediated Smad-independent IKK/NF-kappaB and JNK/AP-1 acti-vation. Cell Signal 2011; 23:222–7.
38. Chen F, Du Y, Zhang Z, Chen G, Zhang M, Shu HB, Zhai Z, Chen D. Syntenin nega-tively regulates TRAF6-mediated IL-1R/TLR4 signaling. Cell Signal 2008; 20:666–74.
39. Tang L, Zhou XD, Wang Q, Zhang L, Wang Y, Li XY, Huang DM. Expression of TRAF6 and pro-inflammatory cytokines through activation of TLR2, TLR4, NOD1, and NOD2 in human periodontal ligament fibroblasts. Arch Oral Biol 2011; 56:1064–72.
40. Qian Y, Liu C, Hartupee J et al. The adaptor Act1 is required for interleukin 17-depen-dent signaling associated with autoimmune and inflammatory disease. Nat Immunol 2007; 8:247–56.
41. Fitzgerald KA, McWhirter SM, Faia KL et al. IKKepsilon and TBK1 are essential com-ponents of the IRF3 signaling pathway. Nat Immunol 2003; 4:491–6.
42. Hacker H, Karin M. Regulation and function of IKK and IKK-related kinases. Sci STKE 2006; 2006:re13.
43. Shen F, Gaffen SL. Structure-function relationships in the IL-17 receptor: implications for signal transduction and therapy. Cytokine 2008; 41:92–104.
44. Leonardi C, Matheson R, Zachariae C, Cameron G, Li L, Edson-Heredia E, Braun D, Banerjee S. Anti-interleukin-17 monoclonal antibody ixekizumab in chronic plaque pso-riasis. N Engl J Med 2012; 366:1190–9.